Tags

Type your tag names separated by a space and hit enter

Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience.
Acta Trop. 2005 Nov-Dec; 96(2-3):168-76.AT

Abstract

Chemotherapy is widely acknowledged as the most important, rapid and cost-effective method of reducing morbidity due to schistosome infections. The discovery of praziquantel in the 1970s has been a breakthrough for treatment of patients infected with schistosomes, including Schistosoma japonicum in China, and entire communities at risk of schistosomiasis. Praziquantel is usually administered in a single oral dose and has no or only mild and transient side effects. The drug is highly efficacious against S. japonicum, both in patients with acute and chronic stages of the infection, among subjects with extensive hepatosplenic involvement, and in patients with other complicated diseases. The cost of praziquantel has been reduced significantly over the past years. Hence, praziquantel has become the backbone of the national schistosomiasis control programme in China and in other countries where the disease remains endemic, most notably in sub-Saharan Africa. Chemotherapy with praziquantel also plays a role in transmission control of schistosomiasis, although transmission interruption cannot be reached by chemotherapy alone. Here, I review 30 years' of experiences gained with the use of praziquantel for clinical treatment and larger-scale control of schistosomiasis japonica in China.

Authors+Show Affiliations

National Institute of Parasitic Diseases, Chinese Centre for Disease Control and Prevention, Shanghai 200025, China. mgchen6@hotmail.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16125657

Citation

Chen, Ming-Gang. "Use of Praziquantel for Clinical Treatment and Morbidity Control of Schistosomiasis Japonica in China: a Review of 30 Years' Experience." Acta Tropica, vol. 96, no. 2-3, 2005, pp. 168-76.
Chen MG. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. Acta Trop. 2005;96(2-3):168-76.
Chen, M. G. (2005). Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. Acta Tropica, 96(2-3), 168-76.
Chen MG. Use of Praziquantel for Clinical Treatment and Morbidity Control of Schistosomiasis Japonica in China: a Review of 30 Years' Experience. Acta Trop. 2005 Nov-Dec;96(2-3):168-76. PubMed PMID: 16125657.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience. A1 - Chen,Ming-Gang, Y1 - 2005/08/25/ PY - 2005/8/30/pubmed PY - 2005/12/15/medline PY - 2005/8/30/entrez SP - 168 EP - 76 JF - Acta tropica JO - Acta Trop VL - 96 IS - 2-3 N2 - Chemotherapy is widely acknowledged as the most important, rapid and cost-effective method of reducing morbidity due to schistosome infections. The discovery of praziquantel in the 1970s has been a breakthrough for treatment of patients infected with schistosomes, including Schistosoma japonicum in China, and entire communities at risk of schistosomiasis. Praziquantel is usually administered in a single oral dose and has no or only mild and transient side effects. The drug is highly efficacious against S. japonicum, both in patients with acute and chronic stages of the infection, among subjects with extensive hepatosplenic involvement, and in patients with other complicated diseases. The cost of praziquantel has been reduced significantly over the past years. Hence, praziquantel has become the backbone of the national schistosomiasis control programme in China and in other countries where the disease remains endemic, most notably in sub-Saharan Africa. Chemotherapy with praziquantel also plays a role in transmission control of schistosomiasis, although transmission interruption cannot be reached by chemotherapy alone. Here, I review 30 years' of experiences gained with the use of praziquantel for clinical treatment and larger-scale control of schistosomiasis japonica in China. SN - 0001-706X UR - https://www.unboundmedicine.com/medline/citation/16125657/Use_of_praziquantel_for_clinical_treatment_and_morbidity_control_of_schistosomiasis_japonica_in_China:_a_review_of_30_years'_experience_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0001-706X(05)00196-8 DB - PRIME DP - Unbound Medicine ER -